Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | PELP1 | Q8IZL8 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8474404 | 0.86 | PDK1 (0.65) | VCAM1KMT2AALDH1A1PKMPDK1 | |
| SCHEMBL2947165 | 0.86 | PDK1 (0.46) | VCAM1KMT2AALDH1A1PKMPDK1 | |
| SCHEMBL29887339 | 0.86 | PDK1 (0.46) | VCAM1KMT2AALDH1A1PKMPDK1 | |
| SCHEMBL13049965 | 0.85 | KMT2A (0.52) | VCAM1KMT2AALDH1A1PKMPDK1 | |
| SCHEMBL21319 | 0.85 | CASP6 (0.57) | KMT2APDK1LMNAHCAR3MEN1 | |
| SCHEMBL2955997 | 0.84 | KMT2A (0.51) | VCAM1KMT2AALDH1A1PKMPDK1 | |
| SCHEMBL18148190 | 0.83 | VCAM1 (0.57) | VCAM1KMT2AALDH1A1PKMPDK1 | |
| SCHEMBL16016753 | 0.83 | ESR1 (0.55) | KMT2AALDH1A1PKMPDK1LMNA | |
| SCHEMBL21932200 | 0.82 | VCAM1 (0.56) | VCAM1KMT2AALDH1A1PKMPDK1 | |
| SCHEMBL4122879 | 0.82 | VCAM1 (0.58) | VCAM1KMT2AALDH1A1PKMPDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445734-B2 | Photolabile protective groups for improved processes to prepare oligonucleotide arrays | NIGU CHEMIE GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-20100292458-A1 | NOVEL PHOTOLABILE PROTECTIVE GROUPS FOR IMPROVED PROCESSES TO PREPARE OLIGONUCLEOTIDE ARRAYS | NIGU CHEMIE GMBH (DE) | 2010-11-18 | — | — | US | disclosed |
| US-7759513-B2 | Photolabile protective groups for improved processes to prepare oligonucleotide arrays | NIGU CHEMIE GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-20040175741-A1 | Novel photolabile protective groups for improved processes to prepare oligonucleotide arrays | NIGU CHEMIE GMBH (DE) | 2004-09-09 | — | — | US | disclosed |
| WO-2004074300-A2 | NOVEL PHOTOLABILE PROTECTIVE GROUPS FOR IMPROVED PROCESSES TO PREPARE OLIGONUCLEOTIDE ARRAYS | NIGU CHEMIE GMBH (DE) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292458-A1 | NOVEL PHOTOLABILE PROTECTIVE GROUPS FOR IMPROVED PROCESSES TO PREPARE OLIGONUCLEOTIDE ARRAYS | NT5C3B, NSUN2, ERCC4 | VCAM1 3546/4885KMT2A 2382/4885ALDH1A1 867/4885 |
| US-20040175741-A1 | Novel photolabile protective groups for improved processes to prepare oligonucleotide arrays | NT5C3B, NSUN2, DCLRE1B | VCAM1 3745/4885KMT2A 2530/4885ALDH1A1 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.